With its stock down 7.1% over the past month, it is easy to disregard Gerresheimer (ETR:GXI). However, the company's fundamentals look pretty decent, and long-term financials are usually aligned with ...

A consortium including KKR and Warburg Pincus has submitted a non-binding bid for Gerresheimer AG, which makes pens used to ...

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Gerresheimer (0NTI – Research Report), with a price ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Deutsche Bank analyst Falko Friedrichs maintained a Buy rating on Gerresheimer (0NTI – Research Report) today and set a price target of ...

The potential acquisition comes as Gerresheimer AG, known for producing pens for injectable weight loss drugs like Wegovy, has been in preliminary talks with private equity investors regarding a sale.

Prior to this announcement, Gerresheimer's earnings easily covered the dividend, but free cash flows were negative. With the company not bringing in any cash, paying out to shareholders is bound ...

Feb 26 (Reuters) - German packaging and medical equipment maker Gerresheimer (GXIG.DE), opens new tab, which makes pens used to inject weight loss drugs such as Novo Nordisk's (NOVOb.CO), opens ...

Temperature peaks in the manufacturing process are the main cause of delamination in tubular glass vials, which was discovered ...

Exclusive: KKR-Warburg Pincus group submit non-binding bid for Gerresheimer, sources say A consortium including KKR and Warburg Pincus has submitted a non-binding bid for Gerresheimer AG , which ...

FRANKFURT/NEW YORK (Reuters) -A consortium including KKR and Warburg Pincus has submitted a non-binding bid for Gerresheimer AG, which makes pens used to inject weight loss drugs like Wegovy ...

Bengaluru: German packaging and medical equipment maker Gerresheimer, which makes pens used to inject weight loss drugs such as Novo Nordisk's Wegovy, halved its revenue guidance for 2025 on ...